BC’s RepliCel to Launch Cell Therapy in Japan

RepliCel Life Sciences Inc. (RepliCel) has resumed its ‘first-in-Japan strategy,’ in which the company plans to launch its cell therapy products in Japan sooner than anywhere else in the world. The company plans to bring its entire portfolio of products to the market in Japan by 2022. RepliCel is a Vancouver-headquartered regenerative medicine company focused on developing cell therapies for esthetic and orthopedic conditions such as aging/sun-damaged skin, pattern baldness, and chronic tendon regeneration.

Use 'AND' or 'OR' to refine your search.

Use quotes " " to get exact matches or remove them to get more results.